DTDavid H. Van Thiel

David H. Van Thiel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David H. Van Thiel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ultra-Rapid Virological Response, Young Age, Low γ-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-α2a Monotherapy

    by Ahmad Amanzada, Armin Goralczyk, Federico Moriconi, Martina Blaschke, Inga-Marie Schaefer, David van Thiel, Sabine Mihm, Giuliano Ramadori

    Background and Aims The standard treatment regimen for chronic HCV genotype 3 (HCV-G3) hepatitis consists of PEGylated interferon-α (IFN-α) and ribavirin at varying doses ranging from 400 to 1,200 mg and results in response rates of 80%. However, this therapy has substantial side-effects including anemia, is teratogenic, and costly. To reduce the side-effects of therapy, the role of monotherapy consisting of only IFN-α was investigated. Methods A retrospective analysis of individual therapy courses of HCV-G3-infected patients who were treated with IFN-α2a monotherapy or a combination therapy with attention to the treatment outcome and the presence of IL28B rs12979860 and IL28B rs8099917 single-nucleotide polymorphism genotypes was performed. Conventional prognostic features in each case were assessed as well. Results In the study, 15/30 (50%) of patients treated with IFN-α2a monotherapy and 32/36 (89%) treated with combination therapy achieved a sustained virological response (SVR). In addition, 7/11 (64%) of those treated initially with monotherapy and subsequently with combination therapy achieved an SVR. An “ultra-rapid” virological response occurring within 2 weeks of initiation of therapy (p = 0.005), young age (p < 0.001) and low initial γ-GT/ALT-ratio (p = 0.03) were associated with a SVR to IFN-α2a monotherapy. An SVR in those treated with combination therapy was found to be associated with a rapid virological response (RVR) (p = 0.03). The absence of histologic steatosis was associated with SVR in all patient groups (p = 0.01). Therapy duration (24 vs. 48 weeks) did not affect the SVR in either group. As expected, combination therapy resulted in more hematological side-effects than did monotherapy. Conclusions An “ultra-rapid” virological response, young age, low initial γ-GT/ALT-ratio and absence of steatosis were each associated with an SVR in those receiving IFN-α2a monotherapy. Therefore, monotherapy in these patients should still be discussed independently of the existence of the IL28B polymorphisms.


  • Consensus Interferon Used to Treat Prior Partial-Responders to Pegylated Interferon Plus Ribavirin

    by Christopher M. Moore, Magdalena George, David H. Van Thiel

    The response to pegylated interferon (peg-IFN) plus ribavirin therapy remains less than ideal with 40-50% of treated subjects failing to clear the virus. Moreover, retreatment is only minimally effective. Consensus interferon (c-IFN) has been shown to be efficacious in HCV genotype 1 patients who have failed therapy with peg-IFN. To evaluated the response to re-treatment of peg-IFN plus ribavirin partial-responders with c-IFN plus ribavirin. Forty-two subjects who had previously failed to clear virus after treatment with peg-IFN plus ribavirin were treated with c-IFN (15 μg/day) plus ribavirin (800-1,200 mg/day) until 12 months of therapy or a total of six consecutive months of PCR negativity was achieved. The study population consisted predominantly of males (71%), Caucasians (76%), with African Americans comprising the remaining 24%, subjects with HCV genotype 1 infection (81%) and 21% had cirrhosis by liver biopsy. The overall SVR rate was 29%. The only pretreatment variable that distinguished responders from partial-responders was the serum triglyceride level. The use of c-IFN plus ribavirin in the retreatment of prior peg-IFN plus ribavirin partial responders is essentially twice that achieved in prior re-treatment regimens consisting of a second course of peg-IFN plus ribavirin. These results will need to be evaluated against the use of triple therapy consisting of a peg-IFN plus ribavirin and a protease inhibitor. More studies utilizing c-IFN plus ribavirin with either a protease inhibitor or polymerase inhibitor need to be performed as well.


  • Continuous Peritoneal Drainage of Large-Volume Ascites

    by David H. Van Thiel, Christopher M. Moore, Moises Garcia, Magdalena George, Abdul Nadir

    With the increasing population of individuals with cirrhosis, many of whom are not liver transplant candidates, large volume paracentesis as a medical therapy for ascites resistant to diuretic therapy has become increasingly utilized. To determine the safety and efficacy of continuous peritoneal drainage of large-volume ascites in Child Class-C cirrhosis. Subjects with no current clinical or laboratory findings of spontaneous bacterial ascites were studied. Each had a complete medical evaluation to document the etiology and severity of their liver disease as well as the identification of any confounding medical illness. A triple-phase abdominal CT of the abdomen was obtained in each individual to rule out any hepatoma. Upon completion of the above, a pericardiocentesis catheter was placed in the abdomen using the Seldinger technique and the ascites was drained continuously (to gravity) until no additional ascitic fluid could be removed or the total time of drainage was 72 h. The patient’s weight, volume of ascitic fluid removed, ascitic fluid cell counts, ascitic fluid cultures, complete blood count and comprehensive metabolic profile were obtained immediately before and after the peritoneal catheter was removed. HCV cirrhosis accounted for 12 cases and alcoholic liver disease accounted for 8 cases (half the total of 40 cases), with 6 other diseases accounting for the remaining half. The ascitic fluid was drained continuously for 2.5 ± 0.08 days, with a removal of 13.3 ± 0.5 l of ascitic fluid. No clinically significant change in the serum creatinine or ascitic fluid cells count occurred as a result of the procedure. The adverse effects of the procedure were minimal. 63% of the patients experienced some mild discomfort at the catheter insertion site, or local abdominal pain just prior to the removal of the catheter. Two patients developed a small abdominal wall hematoma that required no therapy. No patients experienced peritoneal hemorrhage, infection or renal dysfunction. (1) Continuous large-volume peritoneal drainage by gravity is safe and effective; (2) if the procedure is limited 72 h, no cases of ascitic fluid contamination/infection occur; and (3) it reduces the time between subsequent paracentesis based upon historical data.


  • Open Access

    Non-Viral Causes of Hepatocellular Carcinoma

    by David H. Van Thiel, Guiliano Ramadori

    Introduction Hepatocellular carcinoma (HCC) is a major cause of cancer worldwide. The vast majority of cases occur in individuals with a chronic HBV or HCV infection. In addition, a number of metabolic diseases of the liver are associated with the development of HCC. Pathophysiologic Mechanisms The mechanisms responsible for the progression of the metabolic liver disease and HCC differ from those associated with viral liver disease. Conclusions The purpose of this report is to describe the mechanisms responsible for the disease progression and HCC in case of metabolic liver disease. A secondary goal is to identify the frequency of HCC development in the disorders described.


  • An Assessment of the Accuracy of Hepatic and Splenic Size Based Upon a Clinician’s Physical Examination, a Radiologist’s Impression and the Actual Liver and Spleen Volumes Calculated by CT Scanning

    by Shabbar Sajjad, Moises Garcia, Ahmed Malik, David H. Van Thiel

    Objectives In this study, a radiologist’s impression of liver and spleen size based on computed tomography (CT) images, calculated liver and spleen volumes as determined radiologically, and findings of a hepatologist were compared. Methods One hundred and ninety-four consecutive subjects seen by a hepatologist were evaluated clinically and radiologically. Liver and spleen volumes were calculated based on CT images and compared to radiologist’s impression and to expected liver volume based on body weight. Covariate analysis was used to determine the relationships between different variables, and a value of P < 0.05 was considered to be significant. Results Liver volume calculated on the basis of CT scans correlated to liver size based on the hepatologist’s clinical exam but not to the radiologist’s impression of liver size. In contrast, spleen volume based on CT scans, splenic size based upon radiologist’s impression, and clinician’s assessment all correlated well. Conclusions A variety of biases determine and/or affect the radiologist’s assessment of liver size but not of splenic size.


  • Hepatic Iron Quantitation and Its Relationship with Disease Measures and Histologically Assessed Iron Content

    by Shabbar Sajjad, Moises Garcia, Ahmed Malik, David H. Van Thiel

    Purpose The study was undertaken to determine the relationships between the histological finding of hepatic injury, necrosis, fibrosis and iron staining with biochemical measures of hepatic injury and hepatic iron content. Methods One hundred fourteen consecutive subjects undergoing liver biopsy were studied. Data pertaining to biopsy reports, histology activity index, hepatic iron concentration, hepatic iron index, and histological grading of iron were recorded and analyzed using regression analysis. Results Statistical relationships were found between the hepatic iron index, histological grading of iron and hepatic iron concentration, whereas histology activity index was related to hepatic grading of iron, but not to hepatic iron concentration. Conclusions The pathologist’s assessment of the histological grading of iron relates directly to the histology activity index and hepatic iron concentration. Serum measures of iron, total iron-binding capacity and ferritin can be used to monitor hepatic iron content more economically and simply than with hepatic iron concentration measurement on liver biopsy.